Rotigotine: all 77 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Adhesion and Safety of Rotigexole Compared to Neupro®Not yet recruitingNCT07015346Not applicable
• A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's DiseaseRecruitingNCT06702124Phase 3
• A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs SyndromeTerminatedNCT03992196Phase 3Results posted
• A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown CauseTerminatedNCT03728933Phase 3Results posted
• Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational TreatmentTerminatedNCT02365870Phase 4Results posted
• A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's DiseaseCompletedNCT02230904Phase 1Results posted
• Switching From Oral Dopamine Agonists to RotigotineCompletedNCT01976871Phase 4Results posted
• Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And ApathyCompletedNCT01782222Phase 4Results posted
• Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated PainCompletedNCT01744496Phase 4Results posted
• A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's DiseaseCompletedNCT01723904Phase 3Results posted
• A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's DiseaseCompletedNCT01711866Phase 4Results posted
• Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease PatientsCompletedNCT01646268Phase 3Results posted
• Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease PatientsCompletedNCT01646255Phase 3Results posted
• A Dose-ranging Study for SPM 962 in Parkinson's Disease PatientsCompletedNCT01634243Phase 2Results posted
• A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01631825Phase 3Results posted
• A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01631812Phase 2Results posted
• A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease PatientsCompletedNCT01628965Phase 2/3Results posted
• A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01628926Phase 3Results posted
• A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease PatientsCompletedNCT01628848Phase 2Results posted
• Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)CompletedNCT01569464Phase 3Results posted
• A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs SyndromeCompletedNCT01562743Phase 2Results posted
• A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring HemodialysisCompletedNCT01537042Phase 3Results posted
• Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal DysfunctionTerminatedNCT01536015Phase 3Results posted
• Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease PatientsCompletedNCT01523301Phase 4Results posted
• Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs SyndromeCompletedNCT01498120Phase 2Results posted
• Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs SyndromeCompletedNCT01495793Phase 2Results posted
• Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs SyndromeCompletedNCT01455012Phase 4Results posted
• Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor SymptomsCompletedNCT01300819Phase 4Results posted
• Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)CompletedNCT01084551Phase 3Results posted
• Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the BodyCompletedNCT01059903Phase 1Results posted
• Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the BodyCompletedNCT00957944Phase 1Results posted
• Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.CompletedNCT00881894Phase 1Results posted
• A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) PatientsCompletedNCT00666965Phase 2Results posted
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's DiseaseCompletedNCT00599196Phase 3Results posted
• A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing SurgeryCompletedNCT00594464Phase 4Results posted
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's DiseaseCompletedNCT00594386Phase 3Results posted
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.CompletedNCT00594165Phase 3Results posted
• Safety and Tolerability Trial of Switching From Ropinirole to RotigotineCompletedNCT00593606Phase 3Results posted
• A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease PatientsCompletedNCT00537485Phase 2/3Results posted
• Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal PatchCompletedNCT00522379Phase 3Results posted
• Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's DiseaseTerminatedNCT00519532Phase 3Results posted
• An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's DiseaseCompletedNCT00505687Phase 3Results posted
• An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's DiseaseCompletedNCT00501969Phase 3Results posted
• Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)CompletedNCT00498186Phase 2Results posted
• Randomized Evaluation of the 24-Hour Coverage: Efficacy of RotigotineCompletedNCT00474058Phase 3Results posted
• The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.CompletedNCT00464737Phase 2Results posted
• Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS SymptomsCompletedNCT00389831Phase 2Results posted
• Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson SymptomsCompletedNCT00296192Phase 2Results posted
• Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's DiseaseCompletedNCT00292227Phase 1Results posted
• Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's DiseaseCompletedNCT06247410Phase 2
• Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use DisorderCompletedNCT05886582Phase 2
• Dopaminergic Therapy for Frontotemporal Dementia PatientsCompletedNCT04937452Phase 2
• An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.TerminatedNCT04183634Phase 1
• Effects of Dopaminergic Therapy in Patients With Alzheimer's DiseaseCompletedNCT03250741Phase 2
• Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable SensorsStatus unknownNCT03098368Phase 4
• Non Motors Aspects in De Novo Parkinson's DiseaseStatus unknownNCT02786667Phase 3
• Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's DiseaseCompletedNCT02728947Phase 1
• Irritation and Sensitization Potential of Repeat Applications of Rotigotine PatchCompletedNCT02727205Phase 1
• Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of DiseaseTerminatedNCT02103465Phase 2
• Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean SubjectsCompletedNCT01964573Phase 1
• Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian SubjectsCompletedNCT01854216Phase 1
• Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs SyndromeCompletedNCT01823770Phase 4
• Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female SubjectsCompletedNCT01761526Phase 1
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese SubjectsCompletedNCT01675024Phase 1
• Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese SubjectsCompletedNCT01565018Phase 1
• Study to Compare Adhesiveness of Two Different Rotigotine Patch FormulationsCompletedNCT01338896Phase 1
• Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post StrokeCompletedNCT00663338Phase 2
• Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome SubjectsCompletedNCT00498108Phase 3
• A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs SyndromeCompletedNCT00275236Phase 3
• An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs SyndromeCompletedNCT00263068Phase 3
• Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on LevodopaCompletedNCT00244387Phase 3
• A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's DiseaseCompletedNCT00243971Phase 3
• A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's DiseaseCompletedNCT00243945Phase 3
• A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's DiseaseCompletedNCT00242008Phase 3
• Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg SyndromeCompletedNCT00136045Phase 3
• Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs SyndromeCompletedNCT00135993Phase 3
• Treatment of Parkinson's Disease With a Transdermal Skin PatchCompletedNCT00001931Phase 2

← Rotigotine overview